Predictors of Response to Topical Ruxolitinib in Non-segmental Vitiligo: A Narrative Review - PubMed
5 hours ago
- #ruxolitinib
- #JAK inhibitors
- #vitiligo
- Topical ruxolitinib 1.5% cream is the first approved therapy for repigmentation in non-segmental vitiligo.
- Anatomical site is a consistent predictor of response, with facial lesions showing the highest repigmentation rates and acral areas demonstrating poor response.
- Early clinical improvement is associated with better long-term outcomes.
- Long-term data indicate that repigmentation can persist after treatment discontinuation in many patients.
- Demographic and disease-related variables (age, sex, disease duration, phototype) show mixed results across studies.
- Adjunctive narrowband UVB improves repigmentation in initial non-responders but offers limited benefit in early responders.
- Exploratory biomarker data suggest Th2 cytokine profiles and reductions in CXCL10 levels may be linked to response, though unvalidated.
- Anatomical location and early clinical response are the most reliable indicators of ruxolitinib efficacy.
- Further studies with standardized endpoints and predictive modeling are needed for individualized treatment strategies.